ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0956

Mapping Metabolic Changes in Skin Fibrosis in Systemic Sclerosis by Spatial Proteomics

Veda Devakumar1, Yi-Nan Li2, Tim Filla3, Aleix Rius Rigau4, Andrea-Hermina Györfi5, Bilgesu Safak Tümerdem6, Ranjana Neelagar7, Minrui Liang8, Christina Bergmann9, Georg Schett10, Jörg Distler11 and Alexandru-Emil Matei12, 1Heinrich Heine University, University Clinic Düsseldorf, Düsseödorf, 2University Hospital of Düsseldorf, Düsseldorf, Germany, 3Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, 4Department of Internal Medicine 3, Rheumatology and Clinical Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen. Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 5Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, 6Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, 7Heinrich Heine University Duesseldorf, University Hospital Duesseldorf, Düsseldorf, Nordrhein-Westfalen, Germany, 8Huashan Hospital, Fudan University, Shanghai, China (People's Republic), 9Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 10Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 11University Hospital Duesseldorf and HHU, Duesseldorf, Germany, 12Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany

Meeting: ACR Convergence 2025

Keywords: Imaging, metabolomics, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0955–0977) Systemic Sclerosis & Related Disorders – Basic Science Poster I

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Several tissue resident populations undergo metabolic reprogramming during tissue fibrosis as a phenotypic adaptation to their changing metabolic demands. However, these shifts in metabolic profiles in fibrotic tissues have not been previously studied at single cell level with spatial resolution. Furthermore, the spatial cellular organization within metabolic niches in fibrotic tissues was not explored until now.Here we aimed to identify and map distinct metabolically-defined fibroblast, macrophage and endothelial cell subsets in SSc skin, characterize their cellular metabolic microenvironments, and evaluate their association with progression of skin fibrosis in SSc.

Methods: Sections from skin biopsies of nine SSc patients and seven controls were prepared. Imaging mass cytometry (IMC), a spatial proteomics technique, was employed. An IMC panel of 38 metal-labelled antibodies, of which 22 antibodies targeting key enzymes and signalling molecules in several metabolic pathways was designed and validated in human skin. Data analysis was performed as described. The glycolysis or TCA/OXPHOS scores calculated with this approach robustly correlate with the activities of the respective pathways, as determined by functional assays.

Results: We analyzed the expression of key regulators of metabolic pathways such as glycolysis, tricarboxylic acid (TCA) cycle, oxidative phosphorylation (OXPHOS), fatty acid oxidation and synthesis, aminoacid internalization, pentose phosphate pathway, hypoxia, reactive oxygen species production as well as of regulators of mitochondrial dynamics, collectively termed as metabolic regulome, in SSc and control skin.Dermal cells of SSc patients with progressive skin fibrosis had a remarkably distinct metabolic regulome compared with patients with stable skin fibrosis and to controls, with upregulation of glycolysis and TCA/OXPHOS scores.Unbiased fibroblast clustering identified eight distinct fibroblasts subsets defined by their metabolic regulome. Of these, a subpopulation of fibroblasts with high expression of glycolysis and TCA/OXPHOS enzymes (termed Methi Fib) was upregulated in SSc patients with progressive skin fibrosis, and expressed high levels of markers of activated fibroblasts, such as αSMA and FAP. The metabolically-defined fibroblast subsets formed niches with endothelial cells and macrophages with similar levels of metabolic pathway activities, e.g. the Methi fibroblasts were located in spatial proximity to endothelial cells and macrophages that expressed high levels of glycolysis and TCA/OXPHOS enzymes.

Conclusion: We identified distinct metabolically-defined subsets fibroblasts in SSc and control skin, with an enrichment of metabolically highly active fibroblasts in progressive skin fibrosis. This fibroblast subset expressed myofibroblast markers and formed niches with endothelial cells and macrophages with a similar metabolic profile. Thus, metabolic phenotyping of fibroblasts and their niches by IMC-based spatial proteomics might identify SSc patients at risk for progression of skin fibrosis.


Disclosures: V. Devakumar: None; Y. Li: None; T. Filla: None; A. Rius Rigau: None; A. Györfi: AbbVie, 6, Boehringer-Ingelheim, 6; B. Tümerdem: None; R. Neelagar: None; M. Liang: None; C. Bergmann: Kyverna Therapeutics, Inc., 5; G. Schett: Cabaletta, 6, Eli Lilly, 6, Janssen, 6, Kyverna, 6, Novartis, 6, UCB, 6; J. Distler: 4D Science, 8, 11, Actelion, 2, 6, Active Biotech, 2, 6, Anamar, 2, 6, Array Biopharma, 2, 6, ARXX Therapeutics, 2, 6, aTyr Pharma, 2, 6, Bayer Pharma, 2, 6, BMS (Bristol-Myers Squibb), 2, 6, Boehringer Ingelheim, 2, 6, Celgene, 2, 6, FibroCure, 4, Galapagos, 2, 6, GSK, 2, 6, Inventiva, 2, 6, JB Therapeutics, 2, 6, Medac, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Redx Pharma, 2, 6, RuiYi, 2, 6, Sanofi-Aventis, 2, 6, UCB, 2, 6; A. Matei: None.

To cite this abstract in AMA style:

Devakumar V, Li Y, Filla T, Rius Rigau A, Györfi A, Tümerdem B, Neelagar R, Liang M, Bergmann C, Schett G, Distler J, Matei A. Mapping Metabolic Changes in Skin Fibrosis in Systemic Sclerosis by Spatial Proteomics [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/mapping-metabolic-changes-in-skin-fibrosis-in-systemic-sclerosis-by-spatial-proteomics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mapping-metabolic-changes-in-skin-fibrosis-in-systemic-sclerosis-by-spatial-proteomics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology